For personal use only. on May 2, 2017. by guest www.bloodjournal.org From 2
INTRODUCTION
Congenital deficiency of coagulation factor (F) XI is associated with postoperative or posttraumatic bleeding, especially in tissues with robust fibrinolytic activity. 1 When blood is exposed to negatively charged surfaces in vitro, plasma FXII is converted to the protease FXIIa, which catalyzes the activation of FXI to FXIa, leading to the activation of FIX and subsequent thrombin generation. FXI can also be activated by thrombin or FXIa. 2 Since FXII deficiency does not affect hemostasis, the hemostatic function of FXI may well be manifested through feedback activation by thrombin generated by exposure of blood to tissue factor (TF). 3 In addition to activation of FIX, FXIa can also promote thrombin generation through direct activation of factors X, V and VIII, 4, 5, 6 suggesting that it can support hemostasis even in the absence of FIX.
Tissue factor pathway inhibitor (TFPI), a Kunitz-type protease inhibitor, is the primary inhibitor of the tissue factor (TF)/FVIIa/FXa complex, and is essential for life. 7 Endothelial cells and platelets are the primary cells producing TFPI. 8, 9 TFPI is also present in monocytes, 10 and circulates in plasma. 11 The TFPI gene encodes several alternatively spliced products. TFPI-α has 3 Kunitz-type inhibitor domains (K1, K2, K3) and a basic C terminal region. TFPI-β is comprised of the K1 and K2 domains attached to a glycosylphosphatidyl inositol-anchored C terminal moiety. Endothelial cells secrete TFPI-α and express TFPI-β, whereas platelets only present the isoform TFPI-α. TFPI-β and TFPI-α reversibly inhibit FXa through the K2 domain and, in a FXa-dependent manner, the TF-FVIIa complex through the K1 domain, 12, 13 whereas the K3 domain has no known inhibitory function. TFPI-mediated inhibition of the procoagulant activity of TF is required for proper embryonic development and hemostasis. Reduced TFPI levels reversed the hemorrhagic defect and prolonged survival of TF-null mice expressing a low level of human TF. 14 Based on the observation that members of the Kunitz-type class of inhibitors, such as protease nexin 2 and bovine pancreatic trypsin inhibitor (aprotinin), inhibit FXIa activity, 15, 16 and the fact that aprotinin is a close analog of TFPI, we hypothesized that TFPI interacts with FXIa. Here we
For personal use only. on May 2, 2017 . by guest www.bloodjournal.org From demonstrate that TFPI binds FXIa, and that FXIa proteolyzes recombinant TFPI and TFPI derived from platelets and on endothelial cells. Neutralization of endothelial cell TFPI by FXIa results in enhanced FXa and fibrin generation independent of the role of FXIa in the intrinsic pathway of blood coagulation.
Neutralization of TFPI may represent a novel mechanism by which FXIa contributes to thrombin generation during hemostasis, as well as pathologic processes such as thrombosis.
METHODS

Reagents. A list of reagents is included in the Supplemental Methods.
Anti-FXI antibodies. The anti-factor XI antibody, 10C9, binds near the FXIa active site and inhibits FXIa cleavage of a chromogenic substrate (Supplementary Figure S1) . The anti-factor XI antibody, 12F5, also binds near the FXIa active site and inhibits FXIa cleavage of a chromogenic substrate. 5 The antifactor XI antibodies, 1A6 and 14E11, were generated as previously described.
3,17
Cell surface immunoassays and Western blotting. A detailed description can be found in the Supplemental Methods.
Purification of human washed platelets. Human venous blood was drawn in accordance with an IRBapproved protocol from healthy donors and platelets purified as previously described. 18 Platelets were stimulated with 0.5U/ml thrombin and 2µM A23187 for 15min at 37 o C. Subsequently, 10U/ml hirudin was added to neutralize thrombin.
Characterization of FXIa binding and cleavage of rTFPI.
A detailed description can be found in the Supplemental Methods. EDTA was added to stop the reaction. Spectrozyme Xa was added and the rate of substrate hydrolysis was measured at 405nm and converted to FXa concentrations using a standard curve. Alternatively, FXa (0.5nM) in the presence of 20µl of supernatant from quiescent or activated platelets was added to Spectrozyme Xa (0.5mM) in HBS and 0.3%BSA; hydrolysis was monitored at 405nm for 1hr.
Plasma clotting assay.
Human platelet-poor plasma (PPP) was prepared and clotting time measured as previously described. 4 In selected experiments, samples were pretreated at RT for 10min with the anti-FXI antibodies 1A6 (20µg/ml), 10C9 (50µg/ml) or 14E11 (20µg/ml). Plasma (33% final) was incubated for 3min in the presence of vehicle, aPTT reagent (1:600 final) or FXIa (5nM) in HEPES-buffered saline at 37 o C. Subsequently, CaCl 2 (8.3mM final) and diluted Innovin (1:600 final) was added, and time to clot formation was measured. In selected experiments, FXI-, FIX-or FX-depleted plasma was used.
Fibrin generation assay. HUVECs were grown to confluence in 96-well plates and incubated for 3hrs in serum-free medium with 0.3%BSA and 25µM ZnCl 2 , containing 0.5nM TNFα. HUVECs were then incubated for 2hrs with FXIa in serum-free medium and incubated for 10min at 37 o C with 50µM aprotinin to stop the reaction. Alternatively, HUVECs were incubated with citrated plasma for 30min, and reactions stopped with aprotinin and CTI (50µg/ml). HUVECs were washed with HBS before a solution of citrated plasma (33% final) in the presence of 1A6 (20µg/ml) was added and fibrin formation initiated with 8.3mM CaCl 2 . Fibrin formation was measured as change in turbidity at 405nm. The time interval required for the solution turbidity to reach the half-maximal value was defined as T half-max . In selected experiments, a solution of citrated plasma (33% final) and the chromogenic FXIIa and kallikrein substrate S-2302 (0.5mM) was added in Ca 2+ -free HBS and hydrolysis measured at 405nm. 
RESULTS
FXIa binds and cleaves TFPI
Binding studies were performed to characterize the interaction between FXIa and TFPI. FXIa bound to immobilized rTFPI in a FXIa concentration-dependent manner ( Figure 1A ). In contrast, neither active site-blocked FXIa (PPACK-FXIa) nor zymogen FXI, bound immobilized rTFPI. FXIa binding to TFPI was unaffected by the presence of Ca 2+ or Zn 2+ ( Figure 1B ).
Incubation of rTFPI with FXIa in solution led to the disappearance of the TFPI band on an SDS-PAGE gel and the appearance of lower molecular mass bands under non-reducing or reducing conditions ( Figure   1C ). N-terminal sequencing of the bands under non-reducing conditions revealed that the cleavages occurred between K1 and K2 domain (Lys86/Thr87) and within the active sites of the second and third Kunitz (K) domains (K2 -Arg107/Gly108 and K3 -Arg199/Ala200). These sites are identical to those previously reported to be cleaved by plasmin. 19 Western blot analyses of rTFPI under non-reducing conditions with a polyclonal anti-TFPI antibody demonstrated the disappearance of the broad band with increasing time in the presence of FXIa ( Figure   1D ). We found that the presence of Zn 2+ , but not Ca 2+ , increased the rate of TFPI proteolysis by FXIa, leading to the complete disappearance of TFPI after 30min. The presence of aprotinin and the anti-FXI antibody 10C9, which binds near the active site of the FXIa, reduced the ability of FXIa to proteolyze TFPI ( Figure 1E Figure S2) . 
FXIa inhibits the anticoagulant effect of rTFPI in plasma.
We tested the capacity of FXIa to inhibit the anticoagulant function of rTFPI in plasma. The addition of rTFPI increased the TF-induced clotting time of normal plasma from ~50sec to ~170sec (Figure 2A ). Interestingly, when we added an aPTT reagent (ellagic acid) and TF to plasma, the subsequent addition of rTFPI only increased the clotting time from ~50sec to ~80sec, suggesting that the activation of the contact pathway reduced the anticoagulant effect of rTFPI. To determine whether this effect was dependent on the activation of FXI by FXIIa, we performed a plasma clotting assay in the presence of 1A6. Under these conditions, the inhibitor activity of rTFPI was fully recovered ( Figure 2B ). An equivalent effect was observed when we used FXI-depleted plasma, in the presence of the active-site blocking anti-FXIa antibodies, 10C9 or12F5, or in the presence of aprotinin (data not shown).
In order to determine whether the effect of FXIa on the inhibition of TFPI in plasma was independent of the ability of FXIa to activate FIX, 5nM FXIa was added to FXI-depleted plasma, and coagulation initiated by the addition of TF. We found that FXIa blocked the anticoagulant activity of 1nM rTFPI on TF-initiated coagulation ( Figure 2C ). The presence of the FXI antibody, 1A6, which inhibits FIX activation, did not block the effect of FXIa, while addition of either of the FXIa active site domainneutralizing antibodies, 10C9 or 12F5, inhibited the rTFPI-neutralizing effect of FXIa. In control experiments in the absence of TF and rTFPI, the addition of FXIa to FXI-depleted plasma decreased the clotting time to ~150sec; this effect was partially reversed by the addition of either 1A6, 10C9 or12F5 (Supplementary Figure S3) . These results indicate that the inhibition of TFPI by FXIa is independent of the generation of FIX, based on the fact that 1A6 was not able to block the ability of FXIa to reverse the effect of TFPI. Moreover, the addition of an aPTT reagent to FIX-depleted plasma blocked the anticoagulant effect of rTFPI on TF-initiated coagulation ( Figure 2D ). Importantly, in the presence of 14E11, the anticoagulant activity of rTFPI was recovered. An inhibitory effect of blocking anti-TFPI antibodies was only observed when rTFPI was exogenously added to normal, FXI-or FIX-depleted plasma ( Figure 2E ), or when clotting was initiated with Innovin at a dilution below 1:10,000
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FXIa inhibits the function of TFPI from platelets.
In order to determine whether FXIa was able to inhibit platelet-derived TFPI-α, we activated platelets with thrombin and a Ca 2+ ionophore to induce degranulation and TFPI-α release. After incubation of platelet release with FXIa for 1hr, we observed that the TFPI-α in the platelet supernatant decreased in a FXIa concentration-dependent manner ( Figure 3A ). We next established that supernatant from activated platelets decreased the activation of FX by the TF-FVIIa complex ( Figure 3B ). This effect was completely reversed following the incubation of platelet supernatant with FXIa. Equivalent results were observed following the incubation of the platelet supernatant with antibodies to the TFPI K1 and K2
domains. The addition of the active-site blocking anti-FXIa antibodies 10C9 or 12F5 eliminated the In contrast, the addition of 1A6 had no effect on the ability of FXIa to potentiate FXa generation.
We next determined whether FXIa degradation of platelet-derived TFPI-α decreased the FXa inhibitory activity of TFPI. We measured the cleavage of Spectrozyme Xa by FXa in the presence of supernatant from either quiescent or activated platelets. The supernatant from activated platelets decreased the activity of FXa ( Figure 3C ). The effect was reversed in the presence of FXIa or anti-TFPI antibodies.
FXIa enhances the ability of HUVECs to initiate FXa generation and fibrin formation in plasma.
We tested the ability of FXIa to promote fibrin formation on HUVECs via inhibition of TFPI-β. HUVECs were preincubated with TNFα to induce TF expression, and fibrin generation was measured. In all experiments, plasma was pretreated with 1A6 in order to block the activity of the intrinsic pathway. We Previous studies have shown that Zn 2+ facilitates FXIa-endothelial cell interactions. 21 Our data show that the addition of Zn 2+ decreased the rate of fibrin generation ( Figure 4C ) and increased FXa generation (Supplemental Figure S6C ) in the presence of FXIa. The procoagulant activity of FXIa was completely reversed by the addition of aprotinin, anti-TFPI antibodies or 10C9. In contrast, the addition of 1A6 did TFPI has been shown to be cleaved by serine proteases, such as elastase and plasmin. 22, 23 When compared to several other serine proteases at equivalent concentrations, the ability of FXIa to cleave TFPI K1 was 1 1
found to be similar to the ability of elastase or plasmin to cleave the K1 domain of TFPI ( Figure 5D ).
Neither kallikrein nor FXIIa appeared to cleave the K1 domain of TFPI on HUVECs.
Endogenous FXIa generated in plasma cleaves the K1 domain of TFPI-β and increases fibrin generation on HUVEC
We studied the effects of endogenous generation of FXI by FXIIa in plasma on the ability of TFPI-β to inhibit fibrin formation on HUVECs. We analyzed whether HUVECs or the culture plate could act as a surface for induction of contact activation using a FXIIa/kallikrein chromogenic substrate (S-2302). As shown in Figure 6A , addition of citrated plasma to HUVECs resulted in hydrolysis of S-2302; this reaction was blocked by aprotinin and CTI, indicating that the contact pathway was activated by
HUVECs. We then studied whether FXIa generated by FXIIa inhibited TFPI on HUVECs. Treatment of HUVECs with citrated plasma promoted the cleavage of the K1 domain from TFPI-β; this effect was reversed by the addition of aprotinin ( Figure 6B ). To determine whether endogenous FXIa generated in plasma by HUVECs promoted fibrin formation, HUVECs were preincubated with TNFα to induce TF expression, following by incubation with citrated plasma for 30min; reactions were then stopped with aprotinin and CTI. In selected experiments, citrated plasma was incubated with 14E11, 1A6, 10C9 or aprotinin. Cells were then washed and fibrin generation of recalcified plasma was measured. 1A6 was included in the recalcified plasma in order to block the intrinsic pathway. As shown in Figure 6C , incubation of HUVECs with citrated plasma increased the rate of fibrin generation upon recalcification.
Pretreatment of citrated plasma with 14E11, 1A6 or 10C9 dramatically reduced the rate of fibrin generation. The presence of a blocking anti-TF mAb abrogated fibrin generation (data not show),
suggesting that the endogenous FXIa generated by HUVECs in plasma reduced the anticoagulant activity of cultured ECs, likely via inhibition of TFPI-β. TFPI inhibits the early stages of the blood coagulation cascade through inhibition of the TF-FVIIa complex and FXa. TFPI is an alternatively spliced protein and the major isoforms are TFPI-α and TFPI-β. TFPI-α, which has K1, K2, K3 domain and a basic C terminal region is stored within quiescent platelets and released following platelet activation. TFPI-α reversibly inhibit FXa through the K2 domain and, in a FXa-dependent manner, the TF-FVIIa complex through the K1 domain. 12, 13 While the K3 domain lacks protease inhibitor activity, it is required for the binding of protein S, which acts as a cofactor for the inhibition of FXa by TFPI-α. 24 We observed that FXIa cleaves TFPI-α from platelet releasate and inhibits its capacity to block the TF-FVIIa complex and FXa. We also observed that the anticoagulant effect of rTFPI-α in plasma was blocked by FXIa that was either generated endogenously in plasma by ellagic acid or directly added to plasma. We demonstrated that this effect of FXIa was independent of the generation of FXa, FVa or FIXa by FXIa. Based on our data, the mechanisms by which FXIa inhibits TFPI-α may be explained by the fact that FXIa cleaves TFPI-α between the K1 and K2 domains (Lys86/Thr87) and at the active site of the K2 domain (Arg107/Gly108), which would block the capacity of TFPI-α to inhibit FXa and the TF-FVIIa complex. The interaction of protein S and TFPI requires K3 residues Arg199 and Glu226. 25 The fact that FXIa also cleaves at the active site of the K3 (Arg199/Ala200) domain, suggests that FXIa may block the access of TFPI-α to protein S and inhibit the capacity of protein S to enhance the inhibition of FXa by TFPI-α. In addition to proteolysis of TFPI,
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The activation of endogenous FXI in plasma by the negatively charged substance ellagic acid blocked the anticoagulant effect of rTFPI-α, suggesting that activation of the contact pathway may promote thrombin generation in plasma through inhibition of TFPI. Physiological activators of the contact pathway, such as polyphosphate polymers (polyP) released from platelet-dense granules, have been shown to bind to FXI and enhance FXI autoactivation and FXI activation by thrombin in plasma. 26 As polyP has been shown to inhibit the inhibitory effect of rTFPI on TF-induced clotting time in plasma, 27 perhaps the inhibition of TFPI by polyP is at least partly due to the ability of polyP to enhance FXIa generation. Based on the fact that TFPI-α also binds to polyanions such as cell surface glycosaminoglycan heparan through its basic Cterminal region and neutrophil extracellular traps, perhaps TFPI-α also binds to polyP through its basic Cterminal region and acts as a cofactor for the inhibition of TFPI by FXIa.
TFPI-β is express on endothelial cells, and is comprised of the K1 and K2 domains attached to a glycosylphosphatidyl inositol-anchored C terminus. We observed that the inhibition of HUVEC-derived TFPI-β by FXIa generated endogenously in plasma, resulted in the loss of the K1 domain of TFPI-β and promotion of TF-dependent fibrin formation. The cleavage of TFPI between the K1 and K2 domain at Lys86 explains the appearance of the lower molecular weight bands under non-reducing conditions and the loss of the K1 domain of TFPI-β on HUVECs. We also observed that the inhibition of TFPI-β by Interestingly, in the same study, patients with severe FXI deficiency with a history of bleeding had higher levels of TFPI than asymptomatic patients. 33 Perhaps FXI deficient patients who have relatively mild bleeding problems have lower than normal TFPI levels that compensate for the absence of FXI.
During hemostasis, initiation of coagulation via the extrinsic pathway results in the activation of FX and FIX leading to thrombin generation. FXI activation contributes to the amplification of thrombin generation through the intrinsic pathway. The contributions of both the extrinsic and intrinsic pathways can be downregulated in part by plasma or platelet-derived TFPI through direct inhibition of FXa. Here, we show that TFPI is a substrate of FXIa, and that FXIa is capable of reversing the inhibitory function of platelet-derived TFPI-α, suggesting an additional mechanism by which FXIa may enhance FXa and thrombin generation during hemostasis. As the observed events in the clotting time and fibrin generation assays are specific to the conditions used, further studies would be required to define the effect of FXIa
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on the rate constants of thrombin generation through inhibition of TFPI function, as well as to determine whether these in vitro events occur in the wound environment.
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